These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23689213)

  • 41. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
    Shalviri G; Mohammad K; Majdzadeh R; Gholami K
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
    Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
    Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacovigilance in Germany : It is about time].
    Douros A; Schaefer C; Kreutz R; Garbe E
    Internist (Berl); 2016 Jun; 57(6):616-23. PubMed ID: 27224991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative methods in pharmacovigilance: focus on signal detection.
    Hauben M; Zhou X
    Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Key Elements in Adverse Drug Reactions Safety Signals: Application of Legal Strategies.
    Chen B; Restaino J; Tippett E
    Cancer Treat Res; 2019; 171():47-59. PubMed ID: 30552656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Performance assessment of the Thai National Center for Pharmacovigilance.
    Kaewpanukrungsi W; Anantachoti P
    Int J Risk Saf Med; 2015; 27(4):225-37. PubMed ID: 26756896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
    Ali TB; Schleret TR; Reilly BM; Chen WY; Abagyan R
    PLoS One; 2015; 10(12):e0144337. PubMed ID: 26642212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.
    Hauben M; Reich L
    J Clin Pharmacol; 2005 Apr; 45(4):378-84. PubMed ID: 15778418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study.
    González-Rubio F; Calderón-Larrañaga A; Poblador-Plou B; Navarro-Pemán C; López-Cabañas A; Prados-Torres A
    Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1287-94. PubMed ID: 21702073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FDA Adverse Event Reporting System: Recruiting Doctors to Make Surveillance a Little Less Passive.
    Mann JM
    Food Drug Law J; 2015; 70(3):371-94, i. PubMed ID: 26630821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive modeling of structured electronic health records for adverse drug event detection.
    Zhao J; Henriksson A; Asker L; Boström H
    BMC Med Inform Decis Mak; 2015; 15 Suppl 4(Suppl 4):S1. PubMed ID: 26606038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fusion of nonclinical and clinical data to predict human drug safety.
    Johnson DE
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):185-95. PubMed ID: 23473595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Active pharmacovigilance in China: recent development and future perspectives.
    Li X; Li H; Deng J; Zhu F; Liu Y; Chen W; Yue Z; Ren X; Xia J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):863-871. PubMed ID: 29637279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.